Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

959 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.
Ribera JM, García O, Moreno MJ, Barba P, García-Cadenas I, Mercadal S, Montesinos P, Barrios M, González-Campos J, Martínez-Carballeira D, Gil C, Ribera J, Vives S, Novo A, Cervera M, Serrano J, Lavilla E, Abella E, Tormo M, Amigo ML, Artola MT, Genescà E, Bravo P, García-Belmonte D, García-Guiñón A, Hernández-Rivas JM, Feliu E; PETHEMA Group of the Spanish Society of Hematology. Ribera JM, et al. Among authors: gil c. Cancer. 2019 Aug 15;125(16):2810-2817. doi: 10.1002/cncr.32156. Epub 2019 Apr 23. Cancer. 2019. PMID: 31012967 Free article. Clinical Trial.
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Sanz MA, et al. Blood. 2010 Jun 24;115(25):5137-46. doi: 10.1182/blood-2010-01-266007. Epub 2010 Apr 14. Blood. 2010. PMID: 20393132 Free article. Clinical Trial.
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups. Montesinos P, et al. Blood. 2011 Feb 10;117(6):1799-805. doi: 10.1182/blood-2010-04-277434. Epub 2010 Dec 8. Blood. 2011. PMID: 21148082 Free article. Clinical Trial.
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.
Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups. Barragán E, et al. Haematologica. 2011 Oct;96(10):1470-7. doi: 10.3324/haematol.2011.044933. Epub 2011 Jun 17. Haematologica. 2011. PMID: 21685470 Free PMC article.
Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy.
Kelleher N, Gallardo D, González-Campos J, Hernández-Rivas JM, Montesinos P, Sarrá J, Gil C, Barba P, Guàrdia R, Brunet S, Bernal T, Martínez MP, Abella E, Bermúdez A, Sánchez-Delgado M, Antònia C, Gayoso J, Calbacho M, Ribera JM; Pethema Group, Spanish Society of Hematology. Kelleher N, et al. Among authors: gil c. Leuk Lymphoma. 2016;57(1):86-91. doi: 10.3109/10428194.2015.1040013. Epub 2015 May 12. Leuk Lymphoma. 2016. PMID: 25860236
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM; IC-APL and PETHEMA and HOVON Groups. Sanz MA, et al. Ann Hematol. 2015 Aug;94(8):1347-56. doi: 10.1007/s00277-015-2393-0. Epub 2015 May 15. Ann Hematol. 2015. PMID: 25975975 Clinical Trial.
Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.
Ribera JM, García O, Oriol A, Gil C, Montesinos P, Bernal T, González-Campos J, Lavilla E, Ribera J, Brunet S, Martínez MP, Tormo M, Genescà E, Barba P, Sarrà J, Monteserín MC, Soria B, Colorado M, Cladera A, García-Guiñón A, Calbacho M, Serrano A, Ortín X, Pedreño M, Amigo ML, Escoda L, Feliu E; PETHEMA Group, Spanish Society of Hematology. Ribera JM, et al. Among authors: gil c. Leuk Res. 2016 Feb;41:12-20. doi: 10.1016/j.leukres.2015.11.012. Epub 2015 Dec 2. Leuk Res. 2016. PMID: 26686475 Clinical Trial.
Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
Sanchez R, Ayala R, Alonso RA, Martínez MP, Ribera J, García O, Sanchez-Pina J, Mercadal S, Montesinos P, Martino R, Barba P, González-Campos J, Barrios M, Lavilla E, Gil C, Bernal T, Escoda L, Abella E, Amigo ML, Moreno MJ, Bravo P, Guàrdia R, Hernández-Rivas JM, García-Guiñón A, Piernas S, Ribera JM, Martínez-López J. Sanchez R, et al. Among authors: gil c. Ann Hematol. 2017 Jul;96(7):1069-1075. doi: 10.1007/s00277-017-3002-1. Epub 2017 Apr 27. Ann Hematol. 2017. PMID: 28451802 Free PMC article.
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
Martínez-Cuadrón D, Montesinos P, Vellenga E, Bernal T, Salamero O, Holowiecka A, Brunet S, Gil C, Benavente C, Ribera JM, Pérez-Encinas M, De la Serna J, Esteve J, Rubio V, González-Campos J, Escoda L, Amutio ME, Arnan M, Arias J, Negri S, Lowënberg B, Sanz MA. Martínez-Cuadrón D, et al. Among authors: gil c. Leukemia. 2018 Jan;32(1):21-29. doi: 10.1038/leu.2017.178. Epub 2017 Jun 6. Leukemia. 2018. PMID: 28584252
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A; PETHEMA Group, Spanish Society of Hematology. Ribera JM, et al. Among authors: gil c. Leuk Lymphoma. 2018 Jul;59(7):1634-1643. doi: 10.1080/10428194.2017.1397661. Epub 2017 Nov 22. Leuk Lymphoma. 2018. PMID: 29165013 Clinical Trial.
959 results